Search Results for "En Vivo EVP6124 Alzheimer"

11:54 EDT 30th August 2015 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Potential Saliva Test to Detect Alzheimer’s

Saliva may be a new, easily-accessible, avenue for Alzheimer’s detection. A small study, presented at the 2015 Alzheimer’s Association International Conference in Washington, D.C this week, showe...

Vivo closes eighth fund with $750M

Vivo Capital said it closed Vivo Capital Fund VIII with $750 million. Vivo intends to invest the fund in late-stage pharma and medical device companies in the U.S. and in revenue-stage healthcare comp...

Transition Therapeutics Aims to Amplify the Alzheimer’s Conversation Through Mediaplanet’s “Fighting Alzheimer’s” Campaign

New York, NY (PRWEB) June 19, 2015 With Alzheimer’s being the nation’s sixth-leading cause of death and with no cure and a rapidly increasing number of people suffering, the dedicated com...

Does Amyloid Kill in Alzheimer’s, Heal in MS?

Two groups have recently made strides with amyloid beta (aβ), the supposed main villain in Alzheimer’s disease. But while one group is tackling Alzheimer’s by reducing aβ, the other is tackling ...

Physical exercise could help curb symptoms of Alzheimer's

Three studies (American, Danish and Canadian), presented simultaneously at the Alzheimer's Association International Conference (AAIC), indicate that physical exercise may help people live better...

Forgetfulness and Errors Can Signal Alzheimer’s Decades Before Diagnosis

Mistakes on memory and thought tests may give an indication of the future onset of Alzheimer’s, up to 18 years before diagnosis, according to a new study. More than 2,000 people from Chicago withou...

A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome

Individuals with Down syndrome have an enhanced risk of developing early onset Alzheimer disease. Here, the authors describe the features of Alzheimer disease in Down syndrome and show how understandi...

Vivo doubles up

Finance Vivo doubles up Vivo Capital believes it can put a larger amount of capital to work in the U.S. and China. So the firm closed its eighth fund late last month with $750 million -- its largest t...

Matching PubMed Articles

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density.

In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease.

Prevention of Alzheimer disease The roles of nutrition and primary care.

Risk factors for developing Alzheimer disease include hypercholesterolemia, hypertension, obesity, and diabetes. Due to lack of effective treatments for Alzheimer disease (AD), primary prevention beco...

Long-term Course of Alzheimer Disease in Patients Treated According to the Dutch Dementia Guideline at a Memory Clinic: A "Real-Life" Study.

There is little knowledge of the long-term course of Alzheimer disease (AD) in light of current pharmacological and nonpharmacological interventions provided in a "real-life" setting.

Novel levetiracetam derivatives that are effective against the Alzheimer-like phenotype in mice: Synthesis, in vitro, ex vivo and in vivo efficacy studies.

We have synthesized a series of heptamethylene-linked levetiracetam-huprine and levetiracetam-(6-chloro)tacrine hybrids to hit amyloid, tau and cholinergic pathologies as well as β-amyloid (Aβ)-indu...

The Epidemiology of Dementia and Alzheimer Disease in Portugal: Estimations of Prevalence and Treatment-Costs.

The incidence and prevalence of global dementia and AlzheimerâÄôs disease (AD) increase with age, almost doubling every five years after the sixth decade of life. Demographic aging is a reality in ...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement